
Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Money for AI-powered drug discovery
Antiverse Ltd has reported the discovery of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both of which are...

Hummingbird and Synaffix in $150m ADC deal
Under the deal, Synaffix can earn up to $150m, including upfront and milestone payments, plus royalties on net sales if the ADC resulting from the...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

European VCs join US$105m financing of US Mediar Thx
Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...